{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:53:56Z","timestamp":1781628836241,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018694","name":"HORIZON EUROPE Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["675712"],"award-info":[{"award-number":["675712"]}],"id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007311","name":"Deutsche Kinderkrebsstiftung","doi-asserted-by":"publisher","award":["Deutsche Kinderkrebsstiftung"],"award-info":[{"award-number":["Deutsche Kinderkrebsstiftung"]}],"id":[{"id":"10.13039\/501100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018001","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de lutte contre les Cancers et les leuc\u00e9mies de l'Enfant et de l'Adolescent","doi-asserted-by":"publisher","award":["Soci\u00e9t\u00e9 Fran\u00e7aise de lutte contre les Cancers et les leuc\u00e9mies de l'Enfant et de l'Adolescent"],"award-info":[{"award-number":["Soci\u00e9t\u00e9 Fran\u00e7aise de lutte contre les Cancers et les leuc\u00e9mies de l'Enfant et de l'Adolescent"]}],"id":[{"id":"10.13039\/100018001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Single nucleotide polymorphisms (SNPs) of cancer-immunity relevant genes may decide the extent of tumor immunosurveillance and have clinical significance. The Immuno ALCL trial was designed to investigate whether genetic variability in 13 cancer-immunity relevant genes correlated with clinical features and outcome of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>One hundred eighty patients were enrolled and genotyped for 14 SNPs. Age at diagnosis, progression-free survival, histological subtype and anti-ALK antibody titer data were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>IL10 rs1800872, IL10 rs1800896 and TLR3 rs3775291 variants significantly correlated with age at diagnosis. TLR3 rs3775291 was associated with progression-free survival in a recessive model. Combination of multiple genetic variations showed a trend to associate with post-therapeutic relapse. None of the SNP analyzed associated with histological or clinical parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the low number of patients, our work uncovered potential associations between certain cancer-immunity relevant genes and clinical features of ALK-positive ALCL patients. Associations do not imply causations. However, our work highlighted a possible contribution of the IL10 and TLR3 pathways to ALK-positive ALCL pathogenesis and suggested that several genetic variants in concert may modulate the risk of post-therapeutic relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>clinicaltrial.gov NCT02902874. Registered 07 September 2016 https\/\/clinicaltrials.gov\/study\/NCT02902874.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-025-07410-5","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T14:54:43Z","timestamp":1767106483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of immune relevant single nucleotide polymorphisms with ALK-positive anaplastic large cell lymphoma presentation and outcome: results of the immuno ALCL study"],"prefix":"10.1186","volume":"23","author":[{"given":"Petrazzuolo","family":"Adriana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Carbonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Domenica Elisa","family":"De Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Perez-Lanzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Verg\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Quivoron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Lamant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Brugieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Rigaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Ducassou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Emilie","family":"Dourthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-C\u00e9cile","family":"Le Deley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Damm-Welk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willi","family":"Woessmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Minard-Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Maiuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9334-4405","authenticated-orcid":false,"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"1","key":"7410_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12867-016-0073-9","volume":"17","author":"JK Box","year":"2016","unstructured":"Box JK, Paquet N, Adams MN, Boucher D, Bolderson E, O\u2019Byrne KJ, et al. Nucleophosmin: from structure and function to disease development. BMC Mol Biol. 2016;17(1):19.","journal-title":"BMC Mol Biol"},{"key":"7410_CR2","unstructured":"Leventaki V, Shaw T, Pounds S, Cao X, Ma J, Palacios G, et al. Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma [Internet]. 2024. Available from: https:\/\/www.researchsquare.com\/article\/rs-4145750\/v1."},{"key":"7410_CR3","doi-asserted-by":"crossref","unstructured":"Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer. 2013.","DOI":"10.1038\/nrc3580"},{"key":"7410_CR4","doi-asserted-by":"crossref","unstructured":"Pulford K, Falini B, Banham AH, Codrington D, Roberton H, Hatton C, et al. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood. 2000.","DOI":"10.1182\/blood.V96.4.1605"},{"key":"7410_CR5","doi-asserted-by":"crossref","unstructured":"Ait-Tahar K, Damm-Welk C, Burkhardt B, Zimmermann M, Klapper W, Reiter A, et al. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood. 2010.","DOI":"10.1182\/blood-2009-11-251892"},{"issue":"2","key":"7410_CR6","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/leu.2012.205","volume":"27","author":"L Mussolin","year":"2013","unstructured":"Mussolin L, Damm-Welk C, Pillon M, Zimmermann M, Franceschetto G, Pulford K, et al. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia. 2013;27(2):416\u201322.","journal-title":"Leukemia"},{"key":"7410_CR7","unstructured":"Passoni L, Gallo B, Biganzoli E, Stefanoni R, Massimino M, Di Nicola M, et al. In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas. Haematologica. 2006."},{"issue":"5","key":"7410_CR8","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1158\/0008-5472.CAN-06-4427","volume":"67","author":"K Ait-Tahar","year":"2007","unstructured":"Ait-Tahar K, Barnardo MCN, Pulford K. CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma. Cancer Res. 2007;67(5):1898\u2013901.","journal-title":"Cancer Res"},{"issue":"9","key":"7410_CR9","doi-asserted-by":"publisher","first-page":"e1625688","DOI":"10.1080\/2162402X.2019.1625688","volume":"8","author":"VK Singh","year":"2019","unstructured":"Singh VK, Werner S, Schwalm S, Lennerz V, Ruf S, Stadler S, et al. NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma. Oncoimmunology. 2019;8(9):e1625688.","journal-title":"Oncoimmunology"},{"key":"7410_CR10","doi-asserted-by":"crossref","unstructured":"Prokoph N, Larose H, Lim MS, Burke GAA, Turner SD. Treatment options for paediatric anaplastic large cell lymphoma (ALCL): current standard and beyond. Cancers (Basel). 2018;10(4).","DOI":"10.3390\/cancers10040099"},{"issue":"6","key":"7410_CR11","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1182\/bloodadvances.2024014745","volume":"9","author":"LJ Marks","year":"2025","unstructured":"Marks LJ, Ritter V, Agrusa JE, Kamdar KY, Rivers J, Gardner R, et al. Pediatric relapsed\/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era. Blood Adv. 2025;9(6):1356\u201365.","journal-title":"Blood Adv"},{"issue":"8","key":"7410_CR12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41419-021-03997-x","volume":"12","author":"A Petrazzuolo","year":"2021","unstructured":"Petrazzuolo A, Perez-Lanzon M, Martins I, Liu P, Kepp O, Minard-Colin V, et al. Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce Immunogenic cell death through on-target effects. Cell Death Dis. 2021;12(8):713.","journal-title":"Cell Death Dis"},{"key":"7410_CR13","doi-asserted-by":"crossref","unstructured":"Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, et al. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nat Commun. 2019.","DOI":"10.1038\/s41467-019-09838-y"},{"issue":"3","key":"7410_CR14","doi-asserted-by":"publisher","first-page":"e0152448","DOI":"10.1371\/journal.pone.0152448","volume":"11","author":"W Dong","year":"2016","unstructured":"Dong W, Gong M, Shi Z, Xiao J, Zhang J, Peng J. Programmed cell Death-1 polymorphisms decrease the cancer risk: A Meta-Analysis involving twelve Case-Control studies. PLoS ONE. 2016;11(3):e0152448.","journal-title":"PLoS ONE"},{"key":"7410_CR15","doi-asserted-by":"publisher","first-page":"878507","DOI":"10.3389\/fonc.2022.878507","volume":"12","author":"H Wan","year":"2022","unstructured":"Wan H, Zhou H, Feng Y, Chen Y, Zhu L, Mi Y. Comprehensive analysis of 29,464 cancer cases and 35,858 controls to investigate the effect of the cytotoxic T-Lymphocyte antigen 4 gene rs231775 A\/G polymorphism on cancer risk. Front Oncol. 2022;12:878507.","journal-title":"Front Oncol"},{"issue":"12","key":"7410_CR16","doi-asserted-by":"publisher","first-page":"e83710","DOI":"10.1371\/journal.pone.0083710","volume":"8","author":"Q Yan","year":"2013","unstructured":"Yan Q, Chen P, Lu A, Zhao P, Gu A. Association between CTLA-4 60G\/A and \u2013\u20091661A\/G polymorphisms and the risk of cancers: a meta-analysis. PLoS ONE. 2013;8(12):e83710.","journal-title":"PLoS ONE"},{"key":"7410_CR17","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1186\/1471-2407-10-522","volume":"10","author":"J Zheng","year":"2010","unstructured":"Zheng J, Yu X, Jiang L, Xiao M, Bai B, Lu J, et al. Association between the cytotoxic T-lymphocyte antigen 4\u2009+\u200949G\u2009>\u2009A polymorphism and cancer risk: a meta-analysis. BMC Cancer. 2010;10:522.","journal-title":"BMC Cancer"},{"key":"7410_CR18","doi-asserted-by":"crossref","unstructured":"Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science (1979). 2015.","DOI":"10.1126\/science.aad0779"},{"key":"7410_CR19","doi-asserted-by":"crossref","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007.","DOI":"10.1038\/nm1622"},{"issue":"10","key":"7410_CR20","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2028","volume":"15","author":"F Ghiringhelli","year":"2009","unstructured":"Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1\u0392-dependent adaptive immunity against tumors. Nat Med. 2009;15(10):1170\u20138.","journal-title":"Nat Med"},{"issue":"3","key":"7410_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/mpo.2950170305","volume":"17","author":"L Brugieres","year":"1989","unstructured":"Brugieres L, Caillaud JM, Patte C, Rodary C, Bernard A, Kalifa C, et al. Malignant histiocytosis: therapeutic results in 27 children treated with a single polychemotherapy regimen. Med Pediatr Oncol. 1989;17(3):193\u20136.","journal-title":"Med Pediatr Oncol"},{"key":"7410_CR22","doi-asserted-by":"crossref","unstructured":"Mussolin L, Le Deley MC, Carraro E, Damm-Welk C, Attarbaschi A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: long term results of the international ALCL99 trial. Cancers (Basel). 2020;12(10).","DOI":"10.3390\/cancers12102747"},{"issue":"2","key":"7410_CR23","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2159-8290.CD-20-0465","volume":"11","author":"J Le Naour","year":"2021","unstructured":"Le Naour J, Liu P, Zhao L, Adjemian S, Sztupinszki Z, Taieb J, et al. A TLR3 ligand reestablishes chemotherapeutic responses in the context of FPR1 deficiency. Cancer Discov. 2021;11(2):408\u201323.","journal-title":"Cancer Discov"},{"key":"7410_CR24","doi-asserted-by":"crossref","unstructured":"Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. Cancer cell\u2013autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014.","DOI":"10.1038\/nm.3708"},{"key":"7410_CR25","doi-asserted-by":"crossref","unstructured":"Lu S, Pardini B, Cheng B, Naccarati A, Huhn S, Vymetalkova V, et al. Single nucleotide polymorphisms within interferon signaling pathway genes are associated with colorectal cancer susceptibility and survival. PLoS ONE. 2014;9(10).","DOI":"10.1371\/journal.pone.0111061"},{"key":"7410_CR26","doi-asserted-by":"crossref","unstructured":"Li L, Xiong W, Li D, Cao J. Association of Interleukin-10 polymorphism (rs1800896, rs1800871, and rs1800872) with breast cancer risk: an updated meta-analysis based on different ethnic groups. Front Genet. 2022;13.","DOI":"10.3389\/fgene.2022.829283"},{"key":"7410_CR27","volume-title":"A meta-analysis of associations of IL-10 gene polymorphisms with acute leukemia susceptibility","author":"YX Fan","year":"2023","unstructured":"Fan YX, Chen LR, Gan RX, Yin SJ, Wang P, Meng R, et al. A meta-analysis of associations of IL-10 gene polymorphisms with acute leukemia susceptibility. Volume 170. Cytokine: Academic; 2023."},{"key":"7410_CR28","doi-asserted-by":"crossref","unstructured":"Nomizo T, Ozasa H, Tsuji T, Funazo T, Yasuda Y, Yoshida H, et al. Clinical impact of single nucleotide polymorphism in PD-L1 on response to nivolumab for advanced non-small-cell lung cancer patients. Sci Rep. 2017;7.","DOI":"10.1038\/srep45124"},{"key":"7410_CR29","doi-asserted-by":"crossref","unstructured":"Hashemi M, Karami S, Sarabandi S, Moazeni-Roodi A, Ma\u0142ecki A, Ghavami S, et al. Association between PD-1 and PD-l1 polymorphisms and the risk of cancer: a meta-analysis of case-control studies. Cancers (Basel). 2019;11(8).","DOI":"10.3390\/cancers11081150"},{"key":"7410_CR30","doi-asserted-by":"crossref","unstructured":"Geng P, Zhao X, Xiang L, Liao Y, Wang N, Ou J, et al. Distinct role of CD86 polymorphisms (rs1129055, rs17281995) in risk of cancer: evidence from a meta- analysis. PLoS ONE. 2014;9(11).","DOI":"10.1371\/journal.pone.0109131"},{"issue":"39","key":"7410_CR31","doi-asserted-by":"publisher","first-page":"66204","DOI":"10.18632\/oncotarget.19857","volume":"8","author":"H Chen","year":"2017","unstructured":"Chen H, Tang J, Shen N, Ren K. Interleukin 10 gene rs1800896 polymorphism is associated with the risk of prostate cancer. Oncotarget. 2017;8(39):66204\u201314.","journal-title":"Oncotarget"},{"issue":"35","key":"7410_CR32","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1200\/JCO.2011.36.5411","volume":"29","author":"L Lamant","year":"2011","unstructured":"Lamant L, McCarthy K, D\u2019Amore E, Klapper W, Nakagawa A, Fraga M, et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol. 2011;29(35):4669\u201376.","journal-title":"J Clin Oncol"},{"key":"7410_CR33","doi-asserted-by":"crossref","unstructured":"Montes-Mojarro IA, Steinhilber J, Bonzheim I, Quintanilla-Martinez L, Fend F. The pathological spectrum of systemic anaplastic large cell lymphoma (ALCL). Cancers (Basel). 2018;10(4).","DOI":"10.3390\/cancers10040107"},{"key":"7410_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc2291","volume":"8","author":"R Chiarle","year":"2008","unstructured":"Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8:11\u201323.","journal-title":"Nat Rev Cancer"},{"key":"7410_CR35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1146\/annurev-immunol-032414-112043","volume":"33","author":"SR Woo","year":"2015","unstructured":"Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol. 2015;33:445\u201374.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"7410_CR36","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/cr.2016.149","volume":"27","author":"L Corrales","year":"2017","unstructured":"Corrales L, Matson V, Flood B, Spranger S, Gajewski TF. Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 2017;27(1):96\u2013108.","journal-title":"Cell Res"},{"issue":"1","key":"7410_CR37","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1038\/s41598-019-39984-8","volume":"9","author":"V Gosu","year":"2019","unstructured":"Gosu V, Son S, Shin D, Song KD. Insights into the dynamic nature of the dsRNA-bound TLR3 complex. Sci Rep. 2019;9(1):3652.","journal-title":"Sci Rep"},{"key":"7410_CR38","doi-asserted-by":"crossref","unstructured":"Rigaud C, Kn\u00f6rr F, Brugi\u00e8res L, Woessmann W. Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents. Best Pract Res Clin Haematol. 2023;36(1):101461.","DOI":"10.1016\/j.beha.2023.101444"},{"issue":"14","key":"7410_CR39","first-page":"1657","volume":"136","author":"N Prokoph","year":"2020","unstructured":"Prokoph N, Probst NA, Lee LC, Monahan JM, Matthews JD, Liang HC, et al. IL10RA modulates Crizotinib sensitivity in NPM1-ALK\u2009+\u2009anaplastic large cell lymphoma. Blood. 2020;136(14):1657\u201369.","journal-title":"Blood"},{"key":"7410_CR40","doi-asserted-by":"crossref","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u201368.","DOI":"10.1038\/s41577-020-0306-5"},{"issue":"11","key":"7410_CR41","doi-asserted-by":"publisher","first-page":"e109131","DOI":"10.1371\/journal.pone.0109131","volume":"9","author":"P Geng","year":"2014","unstructured":"Geng P, Zhao X, Xiang L, Liao Y, Wang N, Ou J, et al. Distinct role of CD86 polymorphisms (rs1129055, rs17281995) in risk of cancer: evidence from a meta-analysis. PLoS ONE. 2014;9(11):e109131.","journal-title":"PLoS ONE"},{"key":"7410_CR42","doi-asserted-by":"publisher","first-page":"650979","DOI":"10.3389\/fimmu.2021.650979","volume":"12","author":"JL Santiago","year":"2021","unstructured":"Santiago JL, S\u00e1nchez-P\u00e9rez L, P\u00e9rez-Flores I, de la Higuera MAM, Romero NC, Querol-Garc\u00eda J, et al. Association of polymorphisms in T-Cell activation Costimulatory\/Inhibitory signal genes with allograft kidney rejection risk. Front Immunol. 2021;12:650979.","journal-title":"Front Immunol"},{"issue":"4","key":"7410_CR43","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1089\/gtmb.2016.0335","volume":"21","author":"K Wang","year":"2017","unstructured":"Wang K, Zhu Q, Lu Y, Lu H, Zhang F, Wang X, et al. CTLA-4\u2009+\u200949 G\/A polymorphism confers autoimmune disease risk: an updated Meta-Analysis. Genet Test Mol Biomarkers. 2017;21(4):222\u20137.","journal-title":"Genet Test Mol Biomarkers"},{"key":"7410_CR44","doi-asserted-by":"publisher","first-page":"598076","DOI":"10.3389\/fmed.2021.598076","volume":"8","author":"W Liu","year":"2021","unstructured":"Liu W, Yang Z, Chen Y, Yang H, Wan X, Zhou X, et al. The association between CTLA-4, CD80\/86, and CD28 gene polymorphisms and rheumatoid arthritis: an original study and Meta-Analysis. Front Med (Lausanne). 2021;8:598076.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"7410_CR45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.5114\/aoms.2012.28593","volume":"8","author":"D Pastuszak-Lewandoska","year":"2012","unstructured":"Pastuszak-Lewandoska D, Sewerynek E, Doma\u0144ska D, G\u0142ady\u015b A, Skrzypczak R, Brzezia\u0144ska E. CTLA-4 gene polymorphisms and their influence on predisposition to autoimmune thyroid diseases (Graves\u2019 disease and hashimoto\u2019s thyroiditis). Arch Med Sci. 2012;8(3):415\u201321.","journal-title":"Arch Med Sci"},{"issue":"1","key":"7410_CR46","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3892\/br.2016.813","volume":"6","author":"M Narooie-Nejad","year":"2017","unstructured":"Narooie-Nejad M, Taji O, Kordi Tamandani DM, Kaykhaei MA. Association of CTLA-4 gene polymorphisms \u2013\u2009318\u00a0C\/T and +\u200949A\/G and hashimoto\u2019s thyroidits in Zahedan, Iran. Biomed Rep. 2017;6(1):108\u201312.","journal-title":"Biomed Rep"},{"issue":"12","key":"7410_CR47","first-page":"4130","volume":"82","author":"H Donner","year":"1997","unstructured":"Donner H, Braun J, Seidl C, Rau H, Finke R, Ventz M, et al. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in hashimoto\u2019s thyroiditis and addison\u2019s disease. J Clin Endocrinol Metab. 1997;82(12):4130\u20132.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9180","key":"7410_CR48","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0140-6736(99)01465-8","volume":"354","author":"B Vaidya","year":"1999","unstructured":"Vaidya B, Imrie H, Perros P, Dickinson J, McCarthy MI, Kendall-Taylor P, et al. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy. Lancet. 1999;354(9180):743\u20134.","journal-title":"Lancet"},{"issue":"5","key":"7410_CR49","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00439-004-1244-1","volume":"116","author":"YH Lee","year":"2005","unstructured":"Lee YH, Harley JB, Nath SK. CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis. Hum Genet. 2005;116(5):361\u20137.","journal-title":"Hum Genet"},{"issue":"8","key":"7410_CR50","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/sj.ejhg.5201214","volume":"12","author":"M Barreto","year":"2004","unstructured":"Barreto M, Santos E, Ferreira R, Fesel C, Fontes MF, Pereira C, et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet. 2004;12(8):620\u20136.","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"7410_CR51","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1034\/j.1399-0039.2000.560407.x","volume":"56","author":"\u00c5 Torinsson Naluai","year":"2000","unstructured":"Torinsson Naluai \u00c5, Nilsson S, Samuelsson L, Gudj\u00f3nsd\u00f3ttir AH, Ascher H, Ek J, et al. The CTLA4\/CD28 gene region on chromosome 2q33 confers susceptibility to Celiac disease in a way possibly distinct from that of type 1 diabetes and other chronic inflammatory disorders. Tissue Antigens. 2000;56(4):350\u20135.","journal-title":"Tissue Antigens"},{"key":"7410_CR52","doi-asserted-by":"crossref","unstructured":"Djilali-Saiah I, Schmitz J, Harfouch-Hammoud E, Mougenot JF, Bach JF, Caillat-Zucman S. CTLA-4 gene polymorphism is associated with predisposition to coeliac disease. Gut. 1998;43(2):187\u20139.","DOI":"10.1136\/gut.43.2.187"},{"issue":"7","key":"7410_CR53","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.humimm.2004.04.007","volume":"65","author":"PA Zalloua","year":"2004","unstructured":"Zalloua PA, Abchee A, Shbaklo H, Zreik TG, Terwedow H, Halaby G, et al. Patients with early onset of type 1 diabetes have significantly higher GG genotype at position 49 of the CTLA4 gene. Hum Immunol. 2004;65(7):719\u201324.","journal-title":"Hum Immunol"},{"issue":"2","key":"7410_CR54","first-page":"653","volume":"86","author":"H Rau","year":"2001","unstructured":"Rau H, Braun J, Donner H, Seissler J, Siegmund T, Usadel KH, et al. The codon 17 polymorphism of the CTLA4 gene in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2001;86(2):653\u20135.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"7410_CR55","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/hmg\/6.8.1275","volume":"6","author":"MP Marron","year":"1997","unstructured":"Marron MP, Raffel LJ, Garchon HJ, Jacob CO, Serrano-Rios M, Martinez Larrad MT, et al. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet. 1997;6(8):1275\u201382.","journal-title":"Hum Mol Genet"},{"issue":"7","key":"7410_CR56","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/hmg\/5.7.1075","volume":"5","author":"L Nistic\u00f2","year":"1996","unstructured":"Nistic\u00f2 L, Buzzetti R, Pritchard LE, Van der Auwera B, Giovannini C, Bosi E, et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belg Diabetes Registry Hum Mol Genet. 1996;5(7):1075\u201380.","journal-title":"Belg Diabetes Registry Hum Mol Genet"},{"key":"7410_CR57","unstructured":"Doo Shin H, Winkler C, Claiborne Stephens J, Bream J, Young H, Goedert JJ et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10 [Internet]. Available from: http:\/\/www.pnas.org."},{"key":"7410_CR58","doi-asserted-by":"crossref","unstructured":"Lin MT, Storer B, Martin PJ, Tseng LH, Gooley T, Chen PJ et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation [Internet]. N Engl J Med. 2003;23. Available from: http:\/\/www.ncbi.nlm.nih.gov.","DOI":"10.1056\/NEJMoa022060"},{"issue":"10","key":"7410_CR59","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1084\/jem.20101568","volume":"208","author":"Y Guo","year":"2011","unstructured":"Guo Y, Audry M, Ciancanelli M, Alsina L, Azevedo J, Herman M, et al. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J Exp Med. 2011;208(10):2083\u201398.","journal-title":"J Exp Med"},{"issue":"2","key":"7410_CR60","doi-asserted-by":"publisher","first-page":"818","DOI":"10.4049\/jimmunol.1102179","volume":"188","author":"M Sironi","year":"2012","unstructured":"Sironi M, Biasin M, Cagliani R, Forni D, De Luca M, Saulle I, et al. A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. J Immunol. 2012;188(2):818\u201323.","journal-title":"J Immunol"},{"issue":"2","key":"7410_CR61","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/jre.12299","volume":"51","author":"RM Sellers","year":"2016","unstructured":"Sellers RM, Payne JB, Yu F, LeVan TD, Walker C, Mikuls TR. TLR4 Asp299Gly polymorphism May be protective against chronic periodontitis. J Periodontal Res. 2016;51(2):203\u201311.","journal-title":"J Periodontal Res"},{"issue":"7","key":"7410_CR62","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.humimm.2015.06.006","volume":"76","author":"Mxuan Han","year":"2015","unstructured":"Han Mxuan, Ding C, Kyung HM. Genetic polymorphisms in pattern recognition receptors and risk of periodontitis: evidence based on 12,793 subjects. Hum Immunol. 2015;76(7):496\u2013504.","journal-title":"Hum Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07410-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07410-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07410-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:58:50Z","timestamp":1781625530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07410-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7410"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07410-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was collected and study was approved by independent ethics committees and national medical authorities and conducted according to the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"GK has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sutro, Tollys, and Vascage. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. GK is in the scientific advisory boards of Hevolution, Institut Servier, and Rejuveron Life Sciences\/Centenara Labs AG. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. Among these patents, one \u201cMethods for weight reduction\u201d (US11905330B1) is relevant to this study. GK\u2019s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. GK\u2019s wife, Laurence Zitvogel, has held research contracts with Glaxo Smyth Kline, Incyte, Lytix, Kaleido, Innovate Pharma, Daiichi Sankyo, Pilege, Merus, Transgene, 9\u00a0m, Tusk and Roche, was on the on the Board of Directors of Transgene, is a cofounder of everImmune, and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. MCM is the inventor of a patent covering therapeutic targeting of cancer, not relevant with this study. The funders had no role in the design of the study; in the writing of the manuscript, or in the decision to publish the results. The other authors declare no competing financial interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1434"}}